EmbryoGen®v2 and BlastGen™New products & protocol updates

OSM MunichSaturday June 28, 2014

The most challenging patients:

Prior miscarriage Failed implantationBiochemical pregnancy lossUnexplained infertility…

IMPROVE RESULTS FOR THE MOST CHALLENGING PATIENTS

75% of patients (= 20-65% PR)

25% of ptts(=0-20% PR)

• Formulation• Protocol

FERTILIZATION,CULTURE, TRANSFER

AVAILABLE ACCORDING TO APPROVAL

NEW SAME

• Price• Volume• Positioning

ORIGIO® Sequential Cleav™

ORIGIO® Sequential Fert™

ORIGIO® Sequential Blast™

NEW SEQUENTIAL MEDIA SYSTEM 2014

EmbryoGen®

4

NEW GM-CSF MEDIA 2014

ORIGIO® Sequential Fert™

UPDATED PRODUCT 2014

ORIGIO® Sequential Fert™

FERTILIZATION CULTURE TRANSFER

− New cleavage medium is not formulated for fert

− No data to support GM-CSF effect on fert.

− ICSI is primary fert method globally

− Dedicated fert medium is considered more beneficial.

~1 cycle/vial

2-3 cycles/vial

75% of patients (= 20-65% PR)

25% of ptts(=0-20% PR)

The right patients at the right price

Low price per cycle = attractive for more patients!

• A Day 3-5 IVF medium containing GM-CSF

• Also based on ORIGIO’s new sequential media line

• Used as stage 2 in a sequential EG/BG protocol (not a 1-step medium)

• For culture and transfer

• 3ml vial

NOT YET AVAILABLE

NEW

EmbryoGen®

ORIGIO ® Sequential Cleav™

ORIGIO® Sequential Fert™

ORIGIO ® Sequential Blast™

NEW SEQUENTIAL MEDIA SYSTEM 2014

ORIGIO® Sequential Fert™ BlastGen™

4

NEW GM-CSF MEDIA SYSTEM 2014

Sep 2014BlastGen® 1205”Non-regulated” markets

Jan 2015BlastGen® 1205European markets (CE)

Dec 2014BlastGen® 1205US market (FDA)

July 2014EmbryoGen® 1204European markets (CE)

June 2014EmbryoGen® 1204US market (FDA)

Feb 2014EmbryoGen® 1204”Non-regulated” markets

8

2014 2015

Q1 Q2 Q3 Q4 Q1

UPDATED PRODUCT AVAILABILITY

FIND RECENT DATA @ www.origio.com

• Prior miscarriage • Failed implantation• Biochemical pregnancy loss• Unexplained infertility